Cardiff Oncology advances onvansertib to Phase 3 in RAS-mutated colorectal cancer after Phase 2 showed 72.2% response rate versus...

UroGen's UGN-103 demonstrated a 94.5% six-month response rate in non-muscle invasive bladder cancer, tracking closely with the approved ZUSDURI...

Regeneron's fianlimab misses statistical significance in melanoma trial despite a 5.1-month PFS improvement in high-dose combination therapy.

SENTI-202 achieved 50% complete remission in Donor X cohort of relapsed/refractory AML patients, with all responders MRD-negative and responses...

BioXcel's IGALMI Approval Decision due November 14, 2026, for at-home agitation treatment in bipolar disorder and schizophrenia.

Envudeucitinib Phase 3 trials show 68% PASI 90 response by Week 24, with early itch relief and scalp psoriasis...

Cardiff Oncology advances onvansertib Phase 3 for RAS-mutated colorectal cancer with 72.2% response rate in Phase 2 trial data.

UroGen's UGN-103 demonstrates 94.5% six-month response rate in NMIBC trial, supporting FDA filing planned for Q3 2026.

Senti Bio's SENTI-202 achieves 50% complete remission in Phase 1 relapsed/refractory AML, with responses durable beyond 21 months using...

Regeneron's fianlimab melanoma trial missed its primary endpoint for progression-free survival, though the high-dose combination showed a 5.1-month numerical...